• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING Back to Search Results
Model Number 24653
Device Problems Premature Activation (1484); Difficult to Advance (2920)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 01/27/2023
Event Type  malfunction  
Manufacturer Narrative
Device eval by manufacturer: returned product consisted of an eluvia self-expanding stent system.The outer sheath, tip, inner sheath and the remainder of the device were checked for damage.Visual examination revealed a kink to the outer sheath at the nosecone.The stent was partially deployed 10mm from the middle sheath.Microscopic and further inspection of the remainder of the device, revealed no other damage or irregularities.Product analysis confirmed the reported event of premature deployment.
 
Event Description
It was reported that the stent was prematurely deployed when advancing onto the guidewire.An eluvia eu, 7x60, 130 cm was selected for use in the superficial femoral artery (sfa) to treat the patient's stenosis.During device preparation, the eluvia delivery system was attempted to be advanced over the amplatz super stiff guidewire 0.035 in, but resistance was encountered.To facilitate advancement, the physician pushed the catheter from the tip, which resulted in a partial stent deployment outside of the patient.Additionally, a polymer-like material was noted on the table, which was suspected to be from the eluvia.Of note, no foreign matter was noted on the eluvia or in the device packaging.The eluvia and amplatz were both replaced in order to complete the procedure.The procedure was completed and there were no adverse consequences reported for the patient.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
Manufacturer (Section G)
BOSTON SCIENTIFIC CORPORATION
ballybrit business park
galway
EI  
Manufacturer Contact
jay johnson
4100 hamline ave n
arden hills, MN 55112
6515810888
MDR Report Key16414527
MDR Text Key309972084
Report Number2124215-2023-06711
Device Sequence Number1
Product Code NIU
Combination Product (y/n)Y
Reporter Country CodeIT
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 02/21/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/21/2023
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date10/22/2023
Device Model Number24653
Device Catalogue Number24653
Device Lot Number0028482136
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer02/14/2023
Is the Reporter a Health Professional? Yes
Date Manufacturer Received01/27/2023
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured10/22/2021
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
-
-